Drugs / T1695
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07169695 | Mar 2026 → Jan 2027 expected | vernal keratoconjunctivitis | Laboratoires Thea | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T1695 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169695 ↗ |
| Route | Other | “The participant should instill T1695.” NCT07169695 ↗ |